In vivo and in vivo effects of amino-acid-based and bicarbonate-buffered peritoneal dialysis solutions with regard to peritoneal transport and cytokines/prostanoids dialysate concentrations

Plum, J; Fußhöller, Andreas; Schoenicke, Gerrit; Busch, Thilo; Erren, C; Fieseler, C; Kirchgessner, Judith; Passlick–Deetjen, Jutta; Grabensee, B

doi:10.1093/ndt/12.8.1652

Cited by 28 publications

(22 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Others have reported that a 2.6% amino acid peritoneal dialysis solution induced an increased loss of macromolecules including albumin and IgG and the small molecular weight amino acids, which was accompanied by an increased prostanoid generation in the peritoneal cavity [ 12 ]. One percent AA solutions were also found to stimulate protein losses and release of prostanoids and several proinflammatory cytokines consistent with an increase in peritoneal blood flow and effective peritoneal surface area [ 13 , 14 ]. In some studies, however, no significant effect on protein losses or release of prostanoids was found [ 20 , 21 ].…”

Section: Discussionmentioning

confidence: 99%

Peritoneal Protein Losses and Cytokine Generation in Automated Peritoneal Dialysis with Combined Amino Acids and Glucose Solutions

Tjiong

Zijlstra

Rietveld

et al. 2007

Mediators of Inflammation

View full text Add to dashboard Cite

Objectives. Protein-energy malnutrition as a consequence of deficient protein intake frequently occurs in peritoneal dialysis (PD) patients. Previously, we showed that peritoneal dialysate containing a mixture of amino acids (AA) and glucose has anabolic effects. However AA-dialysate has been reported to increase intraperitoneal protein and AA losses and the release of proinflammatory cytokines (interleukine-6 (IL-6) and tumor necrosis factor alpha (TNFα)). We investigated the effect of AA plus glucose (AAG) solutions on peritoneal protein losses and cytokine generation. Methods. In 6 patients on standard automated peritoneal dialysis (APD) 12 APD sessions of 6 cycles each were performed during the night using dialysate containing 1.1% AA plus glucose or glucose alone as control. Protein losses and TNFα and IL-6 concentrations were measured in dialysates separately collected from nightly cycling and daytime dwell. Results. The 24 hour-protein losses with AAG (median 6.7 g, range 4.7–9.4 g) were similar to control dialysate (median 6.0 g, range 4.2–9.2 g). Daytime dialysate IL-6 levels were higher after nightly AAG dialysis than after control dialysis (142 pg/ml and 82 pg/ml, respectively, P<.05). TNFα concentrations were very low. Conclusion. Nightly APD with amino acids containing dialysate was associated with an increase in peritoneal IL-6 generation during the day. The addition of AA to standard glucose dialysis solutions did not induce a significant increase of peritoneal protein losses.

show abstract

Section: Discussionmentioning

confidence: 99%

Peritoneal Protein Losses and Cytokine Generation in Automated Peritoneal Dialysis with Combined Amino Acids and Glucose Solutions

Tjiong

Zijlstra

Rietveld

et al. 2007

Mediators of Inflammation

View full text Add to dashboard Cite

show abstract

“…Plum et al [31] and Martikainen et al [32] who detected increased intraperitoneal levels of IL-6 in patients receiving amino-acid-based solutions and linked this effect to better preservation of HPMC. Moreover, it has been demonstrated that the dialysate from patients treated with amino-acid-based solutions contained increased concentrations of PGE 2 [31,33]. One may hypothesize that those increased PGE 2 levels were of mesothelial origin.…”

Section: Discussionmentioning

confidence: 99%

Biocompatibility of a bicarbonate-buffered amino-acid-based solution for peritoneal dialysis

et al. 2008

View full text Add to dashboard Cite

Amino-acid-based peritoneal dialysis (PD) fluids have been developed to improve the nutritional status of PD patients. As they may potentially exacerbate acidosis, an amino-acid-containing solution buffered with bicarbonate (Aminobic) has been proposed to effectively maintain acid-base balance. The aim of this study was to evaluate the mesothelial biocompatibility profile of this solution in comparison with a conventional low-glucose-based fluid. Omentum-derived human peritoneal mesothelial cells (HPMC) were preexposed to test PD solutions for up to 120 min, then allowed to recover in control medium for 24 h, and assessed for heat-shock response, viability, and basal and stimulated cytokine [interleukin (IL)-6] and prostaglandin (PGE(2)) release. Acute exposure of HPMC to conventional low-glucose-based PD solution resulted in a time-dependent increase in heat-shock protein (HSP-72) expression, impaired viability, and reduced ability to release IL-6 in response to stimulation. In contrast, in cells treated with Aminobic, the expression of HSP-72 was significantly lower, and viability and cytokine-producing capacity were preserved and did not differ from those seen in control cells. In addition, exposure to Aminobic increased basal release of IL-6 and PGE(2). These data point to a favorable biocompatibility profile of the amino-acid-based bicarbonate-buffered PD solution toward HPMC.

show abstract

“…Plum et al reported that application of amino acid/bicarbonate-containing PDF resulted in significantly higher dialysate TNF concentrations when compared with glucose/bicarbonate-containing solutions. 9 A limited number of in vivo studies analyzed the effects of different glucose concentrations on IL-6 and TNF-a release from peritoneal or peripheral blood macrophages, monocytes or mesothelial cells. Douvdevani et al studied the in vitro effect of dialysis fluid on the basal and lipopolysaccharide stimulated release of IL-1b and TNF-a by peritoneal macrophages and peripheral blood mononuclear cells (PBMC), and the time course and factors involved in this effect.…”

Section: Discussionmentioning

confidence: 99%

Effect of glucose concentration on peritoneal inflammatory cytokines in continuous ambulatory peritoneal dialysis patients

Sayarlıoğlu

Topal

Sayarlıoğlu

et al. 2004

Mediators of Inflammation

View full text Add to dashboard Cite

OBJECTIVE: It is known that glucose concentrations of peritoneal dialysis solutions are detrimental to the peritoneal membrane. In order to determine the effect of glucose concentration on cytokine levels of peritoneal fluid of continuous ambulatory peritoneal dialysis (CAPD) patients, a cross-sectional study was performed. METHODS: Nine non-diabetic CAPD patients participated in two 8-h dwell sessions of overnight exchanges in consecutive days, with 1.36% and 3.86% glucose containing peritoneal dialysis solutions (Baxter-Eczacibas). Peritoneal dialysis fluid tumor necrosis factor (TNF)-alpha and interleukin (IL)-6 levels were measured. RESULTS: TNF-alpha levels after 1.36% and 3.86% glucose used dwells were 23+/-14 pg/ml and 28+/-4 pg/ml, respectively (p=0.78). The IL-6 levels were 106+/-57 pg/ml and 115+/-63 pg/ml (p=0.81), respectively. CONCLUSION: In our in vivo study we found that the glucose concentration of the conventional lactate-based CAPD solution has no effect on basal IL-6 and TNF-alpha levels of peritoneal fluid. Further in vivo studies with non-lactate-based CAPD solutions are needed in order to determine the effect of glucose concentration per se on cytokine release.

show abstract

In vivo and in vivo effects of amino-acid-based and bicarbonate-buffered peritoneal dialysis solutions with regard to peritoneal transport and cytokines/prostanoids dialysate concentrations

Cited by 28 publications

References 2 publications

Peritoneal Protein Losses and Cytokine Generation in Automated Peritoneal Dialysis with Combined Amino Acids and Glucose Solutions

Peritoneal Protein Losses and Cytokine Generation in Automated Peritoneal Dialysis with Combined Amino Acids and Glucose Solutions

Biocompatibility of a bicarbonate-buffered amino-acid-based solution for peritoneal dialysis

Effect of glucose concentration on peritoneal inflammatory cytokines in continuous ambulatory peritoneal dialysis patients

Contact Info

Product

Resources

About